Bowen Hanes & Co. Inc. trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,240 shares of the biopharmaceutical company’s stock after selling 856 shares during the quarter. Bowen Hanes & Co. Inc.’s holdings in Gilead Sciences were worth $512,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Keel Point LLC raised its holdings in shares of Gilead Sciences by 0.4% in the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 11 shares during the period. West Oak Capital LLC raised its holdings in shares of Gilead Sciences by 0.7% in the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 32 shares during the period. First Heartland Consultants Inc. raised its holdings in shares of Gilead Sciences by 0.4% in the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after buying an additional 39 shares during the period. Westover Capital Advisors LLC raised its holdings in shares of Gilead Sciences by 0.8% in the first quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock worth $378,000 after buying an additional 46 shares during the period. Finally, ARS Investment Partners LLC raised its holdings in shares of Gilead Sciences by 0.9% in the first quarter. ARS Investment Partners LLC now owns 5,610 shares of the biopharmaceutical company’s stock worth $381,000 after buying an additional 50 shares during the period. Hedge funds and other institutional investors own 73.99% of the company’s stock.

Several equities research analysts have recently weighed in on GILD shares. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Jefferies Group LLC reiterated a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a report on Tuesday, July 4th. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 price target on the stock in a report on Monday, July 17th. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 price target on the stock. in a report on Wednesday, June 21st. Finally, Deutsche Bank AG started coverage on Gilead Sciences in a report on Friday, June 23rd. They issued a “buy” rating and a $79.00 price target on the stock. Twelve equities research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $85.43.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/06/gilead-sciences-inc-gild-stake-decreased-by-bowen-hanes-co-inc.html.

Gilead Sciences, Inc. (NASDAQ GILD) opened at 83.51 on Friday. The company has a 50-day moving average price of $80.69 and a 200-day moving average price of $71.56. The stock has a market cap of $109.06 billion, a price-to-earnings ratio of 9.07 and a beta of 1.14. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. During the same quarter in the prior year, the firm earned $3.08 earnings per share. The business’s quarterly revenue was down 8.2% compared to the same quarter last year. Equities research analysts anticipate that Gilead Sciences, Inc. will post $8.75 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were paid a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.49%. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.

In other news, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the completion of the sale, the executive vice president now owns 106,113 shares in the company, valued at $8,051,854.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Gregg H. Alton sold 40,000 shares of the stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the sale, the executive vice president now owns 137,488 shares of the company’s stock, valued at approximately $10,174,112. The disclosure for this sale can be found here. Insiders have sold 486,819 shares of company stock valued at $39,298,919 in the last quarter. Insiders own 1.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.